2024-04-03 |
2024-04-01 |
V
Vente
|
Hamilton James C
Chief Discovery/Trans Medicine
Dirigeant
|
6 000
-2.8%
28,03
168 180
USD
|
6 000
-2.8%
|
28,03
|
168 180
USD
|
|
2024-03-20 |
2024-03-20 |
A
Achat
|
Lu Hongbo
Administrateur non-exécutif
|
1 000
+3.1%
27,50
27 500
USD
|
1 000
+3.1%
|
27,50
|
27 500
USD
|
|
2024-03-20 |
2024-03-19 |
A
Achat
|
Lu Hongbo
Administrateur non-exécutif
|
1 000
+3.2%
28,00
28 000
USD
|
1 000
+3.2%
|
28,00
|
28 000
USD
|
|
2024-03-20 |
2024-03-18 |
A
Achat
|
Lu Hongbo
Administrateur non-exécutif
|
1 000
+3.3%
27,49
27 490
USD
|
1 000
+3.3%
|
27,49
|
27 490
USD
|
|
2024-03-08 |
2024-03-06 |
V
Vente
|
Myszkowski Kenneth Allen
Chief Financial Officer
Dirigeant
|
40 000
-9.1%
35,19
1 407 600
USD
|
40 000
-9.1%
|
35,19
|
1 407 600
USD
|
|
2024-02-02 |
2024-01-31 |
VP
Vente planifiée
|
Anzalone Christopher Richard
Chief Executive Officer
Administrateur exécutif
|
19 730
-0.5%
32,71
645 368
USD
|
19 730
-0.5%
|
32,71
|
645 368
USD
|
|
2024-02-02 |
2024-01-31 |
VP
Vente planifiée
|
Anzalone Christopher Richard
Chief Executive Officer
Administrateur exécutif
|
37 769
-1.0%
32,16
1 214 651
USD
|
37 769
-1.0%
|
32,16
|
1 214 651
USD
|
|
2024-01-17 |
2024-01-12 |
VP
Vente planifiée
|
Hamilton James C
Chief Discovery/Trans Medicine
Dirigeant
|
3 702
-1.7%
37,37
138 344
USD
|
3 702
-1.7%
|
37,37
|
138 344
USD
|
|
2024-01-17 |
2024-01-12 |
VP
Vente planifiée
|
Hamilton James C
Chief Discovery/Trans Medicine
Dirigeant
|
4 238
-1.9%
36,47
154 560
USD
|
4 238
-1.9%
|
36,47
|
154 560
USD
|
|
2024-01-16 |
2024-01-11 |
VP
Vente planifiée
|
Vakiener Victoria
Administrateur non-exécutif
|
1 100
-3.3%
38,84
42 724
USD
|
1 100
-3.3%
|
38,84
|
42 724
USD
|
|
2024-01-16 |
2024-01-11 |
VP
Vente planifiée
|
Vakiener Victoria
Administrateur non-exécutif
|
3 620
-9.9%
37,87
137 089
USD
|
3 620
-9.9%
|
37,87
|
137 089
USD
|
|
2024-01-16 |
2024-01-11 |
VP
Vente planifiée
|
Ferrari Mauro
Administrateur non-exécutif
|
1 000
-1.6%
38,63
38 630
USD
|
1 000
-1.6%
|
38,63
|
38 630
USD
|
|
2024-01-16 |
2024-01-11 |
VP
Vente planifiée
|
Ferrari Mauro
Administrateur non-exécutif
|
2 147
-3.4%
37,80
81 157
USD
|
2 147
-3.4%
|
37,80
|
81 157
USD
|
|
2024-01-16 |
2024-01-11 |
VP
Vente planifiée
|
GIVEN DOUGLAS B
Administrateur non-exécutif
|
1 100
-0.8%
38,55
42 405
USD
|
1 100
-0.8%
|
38,55
|
42 405
USD
|
|
2024-01-16 |
2024-01-11 |
VP
Vente planifiée
|
GIVEN DOUGLAS B
Administrateur non-exécutif
|
1 811
-1.4%
37,76
68 383
USD
|
1 811
-1.4%
|
37,76
|
68 383
USD
|
|
2024-01-16 |
2024-01-11 |
VP
Vente planifiée
|
Waddill William D.
Administrateur non-exécutif
|
1 300
-2.6%
38,59
50 167
USD
|
1 300
-2.6%
|
38,59
|
50 167
USD
|
|
2024-01-16 |
2024-01-11 |
VP
Vente planifiée
|
Waddill William D.
Administrateur non-exécutif
|
2 634
-5.1%
37,81
99 592
USD
|
2 634
-5.1%
|
37,81
|
99 592
USD
|
|
2024-01-08 |
2024-01-05 |
VP
Vente planifiée
|
San Martin Javier
Chief Medical Officer
Dirigeant
|
4 403
-2.2%
35,64
156 923
USD
|
4 403
-2.2%
|
35,64
|
156 923
USD
|
|
2024-01-08 |
2024-01-05 |
VP
Vente planifiée
|
San Martin Javier
Chief Medical Officer
Dirigeant
|
3 100
-1.5%
35,03
108 593
USD
|
3 100
-1.5%
|
35,03
|
108 593
USD
|
|
2024-01-08 |
2024-01-05 |
VP
Vente planifiée
|
San Martin Javier
Chief Medical Officer
Dirigeant
|
800
-0.4%
34,11
27 288
USD
|
800
-0.4%
|
34,11
|
27 288
USD
|
|
2024-01-08 |
2024-01-05 |
VP
Vente planifiée
|
Oliver Tracie
Chief Commercial Officer
Dirigeant
|
74
-0.1%
33,89
2 508
USD
|
74
-0.1%
|
33,89
|
2 508
USD
|
|
2024-01-08 |
2024-01-05 |
VP
Vente planifiée
|
Myszkowski Kenneth Allen
Chief Financial Officer
Dirigeant
|
8 904
-2.0%
35,65
317 428
USD
|
8 904
-2.0%
|
35,65
|
317 428
USD
|
|
2024-01-08 |
2024-01-05 |
VP
Vente planifiée
|
Myszkowski Kenneth Allen
Chief Financial Officer
Dirigeant
|
5 800
-1.3%
34,97
202 826
USD
|
5 800
-1.3%
|
34,97
|
202 826
USD
|
|
2024-01-08 |
2024-01-05 |
VP
Vente planifiée
|
Myszkowski Kenneth Allen
Chief Financial Officer
Dirigeant
|
1 400
-0.3%
34,04
47 656
USD
|
1 400
-0.3%
|
34,04
|
47 656
USD
|
|
2024-01-05 |
2024-01-05 |
VP
Vente planifiée
|
O'Brien Patrick
COO and General Counsel
Dirigeant
|
12 741
-2.7%
35,65
454 217
USD
|
12 741
-2.7%
|
35,65
|
454 217
USD
|
|
2024-01-05 |
2024-01-05 |
VP
Vente planifiée
|
O'Brien Patrick
COO and General Counsel
Dirigeant
|
8 200
-1.7%
34,99
286 918
USD
|
8 200
-1.7%
|
34,99
|
286 918
USD
|
|
2024-01-05 |
2024-01-05 |
VP
Vente planifiée
|
O'Brien Patrick
COO and General Counsel
Dirigeant
|
1 900
-0.4%
33,99
64 581
USD
|
1 900
-0.4%
|
33,99
|
64 581
USD
|
|
2024-01-05 |
2024-01-05 |
VP
Vente planifiée
|
Hamilton James C
Chief Discovery/Trans Medicine
|
10 000
-4.4%
35,00
350 000
USD
|
10 000
-4.4%
|
35,00
|
350 000
USD
|
|
2024-01-05 |
2024-01-05 |
VP
Vente planifiée
|
Hamilton James C
Chief Discovery/Trans Medicine
|
12 343
-5.1%
35,65
440 028
USD
|
12 343
-5.1%
|
35,65
|
440 028
USD
|
|
2024-01-05 |
2024-01-05 |
VP
Vente planifiée
|
Hamilton James C
Chief Discovery/Trans Medicine
|
8 000
-3.2%
34,94
279 520
USD
|
8 000
-3.2%
|
34,94
|
279 520
USD
|
|
2024-01-05 |
2024-01-05 |
VP
Vente planifiée
|
Hamilton James C
Chief Discovery/Trans Medicine
|
1 800
-0.7%
34,00
61 200
USD
|
1 800
-0.7%
|
34,00
|
61 200
USD
|
|
2024-01-05 |
2024-01-04 |
VP
Vente planifiée
|
O'Brien Patrick
COO and General Counsel
Dirigeant
|
1 600
-0.4%
32,63
52 208
USD
|
1 600
-0.4%
|
32,63
|
52 208
USD
|
|
2024-01-05 |
2024-01-03 |
VP
Vente planifiée
|
O'Brien Patrick
COO and General Counsel
Dirigeant
|
1 700
-0.4%
32,65
55 505
USD
|
1 700
-0.4%
|
32,65
|
55 505
USD
|
|
2024-01-05 |
2024-01-03 |
VP
Vente planifiée
|
O'Brien Patrick
COO and General Counsel
Dirigeant
|
400
-0.1%
33,41
13 364
USD
|
400
-0.1%
|
33,41
|
13 364
USD
|
|
2024-01-05 |
2024-01-03 |
VP
Vente planifiée
|
O'Brien Patrick
COO and General Counsel
Dirigeant
|
2 800
-0.7%
32,52
91 056
USD
|
2 800
-0.7%
|
32,52
|
91 056
USD
|
|
2024-01-05 |
2024-01-03 |
VP
Vente planifiée
|
O'Brien Patrick
COO and General Counsel
Dirigeant
|
3 849
-0.9%
31,83
122 514
USD
|
3 849
-0.9%
|
31,83
|
122 514
USD
|
|
2024-01-05 |
2024-01-03 |
VP
Vente planifiée
|
Hamilton James C
Chief Discovery/Trans Medicine
|
500
-0.3%
33,30
16 650
USD
|
500
-0.3%
|
33,30
|
16 650
USD
|
|
2024-01-05 |
2024-01-03 |
VP
Vente planifiée
|
Hamilton James C
Chief Discovery/Trans Medicine
|
2 300
-1.3%
32,52
74 796
USD
|
2 300
-1.3%
|
32,52
|
74 796
USD
|
|
2024-01-05 |
2024-01-03 |
VP
Vente planifiée
|
Hamilton James C
Chief Discovery/Trans Medicine
|
3 500
-1.9%
31,81
111 335
USD
|
3 500
-1.9%
|
31,81
|
111 335
USD
|
|
2024-01-04 |
2024-01-02 |
VP
Vente planifiée
|
Anzalone Christopher Richard
Chief Executive Officer
Administrateur exécutif
|
5 318
-0.1%
31,25
166 188
USD
|
5 318
-0.1%
|
31,25
|
166 188
USD
|
|
2024-01-04 |
2024-01-02 |
VP
Vente planifiée
|
Anzalone Christopher Richard
Chief Executive Officer
Administrateur exécutif
|
4 634
-0.1%
30,74
142 449
USD
|
4 634
-0.1%
|
30,74
|
142 449
USD
|
|
2023-12-22 |
2023-12-20 |
VP
Vente planifiée
|
Anzalone Christopher Richard
Chief Executive Officer
Administrateur exécutif
|
12 000
-0.3%
28,54
342 480
USD
|
12 000
-0.3%
|
28,54
|
342 480
USD
|
|
2023-11-22 |
2023-11-20 |
V
Vente
|
San Martin Javier
Chief Medical Officer
Dirigeant
|
4 942
-3.6%
29,00
143 318
USD
|
4 942
-3.6%
|
29,00
|
143 318
USD
|
|
2023-11-22 |
2023-11-20 |
V
Vente
|
San Martin Javier
Chief Medical Officer
Dirigeant
|
14 758
-9.7%
28,73
423 997
USD
|
14 758
-9.7%
|
28,73
|
423 997
USD
|
|
2023-10-27 |
2023-10-25 |
VP
Vente planifiée
|
Anzalone Christopher Richard
Chief Executive Officer
Administrateur exécutif
|
24 338
-0.6%
24,21
589 223
USD
|
24 338
-0.6%
|
24,21
|
589 223
USD
|
|
2023-10-02 |
2023-09-28 |
V
Vente
|
Vakiener Victoria
Administrateur non-exécutif
|
1 550
-6.7%
26,33
40 812
USD
|
1 550
-6.7%
|
26,33
|
40 812
USD
|
|
2023-09-20 |
2023-09-18 |
VP
Vente planifiée
|
Anzalone Christopher Richard
Chief Executive Officer
Administrateur exécutif
|
26 232
-0.7%
28,27
741 579
USD
|
26 232
-0.7%
|
28,27
|
741 579
USD
|
|
2023-09-20 |
2023-09-18 |
VP
Vente planifiée
|
Anzalone Christopher Richard
Chief Executive Officer
Administrateur exécutif
|
31 523
-0.8%
28,00
882 644
USD
|
31 523
-0.8%
|
28,00
|
882 644
USD
|
|
2023-07-06 |
2023-07-03 |
V
Vente
|
Oliver Tracie
Chief Commercial Officer
Dirigeant
|
8 925
-12.7%
35,31
315 142
USD
|
8 925
-12.7%
|
35,31
|
315 142
USD
|
|
2023-07-05 |
2023-06-30 |
V
Vente
|
Hamilton James C
Chief Discovery/Trans Medicine
|
3 000
-1.6%
35,53
106 590
USD
|
3 000
-1.6%
|
35,53
|
106 590
USD
|
|
2023-06-29 |
2023-06-27 |
V
Vente
|
Myszkowski Kenneth Allen
Chief Financial Officer
Dirigeant
|
15 000
-3.8%
36,20
543 000
USD
|
15 000
-3.8%
|
36,20
|
543 000
USD
|
|
2023-05-08 |
2023-05-05 |
V
Vente
|
GIVEN DOUGLAS B
Administrateur non-exécutif
|
6 500
-5.2%
40,90
265 850
USD
|
6 500
-5.2%
|
40,90
|
265 850
USD
|
|
2023-05-05 |
2023-05-04 |
V
Vente
|
Anzalone Christopher Richard
Chief Executive Officer
Administrateur exécutif
|
25 992
-0.7%
40,02
1 040 200
USD
|
25 992
-0.7%
|
40,02
|
1 040 200
USD
|
|
2023-05-05 |
2023-05-04 |
V
Vente
|
Anzalone Christopher Richard
Chief Executive Officer
Administrateur exécutif
|
24 008
-0.6%
38,97
935 592
USD
|
24 008
-0.6%
|
38,97
|
935 592
USD
|
|
2023-05-05 |
2023-05-03 |
V
Vente
|
Anzalone Christopher Richard
Chief Executive Officer
Administrateur exécutif
|
54 928
-1.4%
39,14
2 149 882
USD
|
54 928
-1.4%
|
39,14
|
2 149 882
USD
|
|
2023-03-06 |
2023-03-03 |
V
Vente
|
OLUKOTUN ADEOYE Y
Administrateur non-exécutif
|
11 350
-59.1%
32,65
370 578
USD
|
11 350
-59.1%
|
32,65
|
370 578
USD
|
|
2023-03-01 |
2023-02-27 |
V
Vente
|
GIVEN DOUGLAS B
Administrateur non-exécutif
|
875
-6.3%
32,62
28 543
USD
|
875
-6.3%
|
32,62
|
28 543
USD
|
|
2023-01-11 |
2023-01-09 |
VP
Vente planifiée
|
Waddill William D.
Administrateur non-exécutif
|
3 200
-10.0%
30,00
96 000
USD
|
3 200
-10.0%
|
30,00
|
96 000
USD
|
|
2023-01-06 |
2023-01-05 |
VP
Vente planifiée
|
O'Brien Patrick
COO and General Counsel
Dirigeant
|
7 500
-1.8%
37,39
280 425
USD
|
7 500
-1.8%
|
37,39
|
280 425
USD
|
|
2023-01-06 |
2023-01-05 |
VP
Vente planifiée
|
O'Brien Patrick
COO and General Counsel
Dirigeant
|
7 500
-1.8%
37,39
280 425
USD
|
7 500
-1.8%
|
37,39
|
280 425
USD
|
|
2023-01-06 |
2023-01-05 |
VP
Vente planifiée
|
Hamilton James C
Chief Discovery/Trans Medicine
|
6 573
-3.3%
37,40
245 830
USD
|
6 573
-3.3%
|
37,40
|
245 830
USD
|
|
2023-01-06 |
2023-01-05 |
VP
Vente planifiée
|
Hamilton James C
Chief Discovery/Trans Medicine
|
7 230
-3.5%
37,40
270 402
USD
|
7 230
-3.5%
|
37,40
|
270 402
USD
|
|
2023-01-05 |
2023-01-03 |
VP
Vente planifiée
|
O'Brien Patrick
COO and General Counsel
Dirigeant
|
270
-0.1%
40,53
10 943
USD
|
270
-0.1%
|
40,53
|
10 943
USD
|
|
2023-01-05 |
2023-01-03 |
VP
Vente planifiée
|
O'Brien Patrick
COO and General Counsel
Dirigeant
|
300
-0.1%
39,55
11 865
USD
|
300
-0.1%
|
39,55
|
11 865
USD
|
|
2023-01-05 |
2023-01-03 |
VP
Vente planifiée
|
O'Brien Patrick
COO and General Counsel
Dirigeant
|
5 286
-1.4%
38,58
203 934
USD
|
5 286
-1.4%
|
38,58
|
203 934
USD
|
|
2023-01-05 |
2023-01-03 |
VP
Vente planifiée
|
O'Brien Patrick
COO and General Counsel
Dirigeant
|
2 894
-0.8%
37,58
108 757
USD
|
2 894
-0.8%
|
37,58
|
108 757
USD
|
|
2023-01-05 |
2023-01-03 |
VP
Vente planifiée
|
O'Brien Patrick
COO and General Counsel
Dirigeant
|
70
-0.0%
40,80
2 856
USD
|
70
-0.0%
|
40,80
|
2 856
USD
|
|
2023-01-05 |
2023-01-03 |
VP
Vente planifiée
|
O'Brien Patrick
COO and General Counsel
Dirigeant
|
500
-0.1%
39,74
19 870
USD
|
500
-0.1%
|
39,74
|
19 870
USD
|
|
2023-01-05 |
2023-01-03 |
VP
Vente planifiée
|
O'Brien Patrick
COO and General Counsel
Dirigeant
|
5 527
-1.5%
38,54
213 011
USD
|
5 527
-1.5%
|
38,54
|
213 011
USD
|
|
2023-01-05 |
2023-01-03 |
VP
Vente planifiée
|
O'Brien Patrick
COO and General Counsel
Dirigeant
|
2 653
-0.7%
37,53
99 567
USD
|
2 653
-0.7%
|
37,53
|
99 567
USD
|
|
2023-01-05 |
2023-01-03 |
VP
Vente planifiée
|
Hamilton James C
Chief Discovery/Trans Medicine
|
247
-0.2%
40,52
10 008
USD
|
247
-0.2%
|
40,52
|
10 008
USD
|
|
2023-01-05 |
2023-01-03 |
VP
Vente planifiée
|
Hamilton James C
Chief Discovery/Trans Medicine
|
300
-0.2%
39,56
11 868
USD
|
300
-0.2%
|
39,56
|
11 868
USD
|
|
2023-01-05 |
2023-01-03 |
VP
Vente planifiée
|
Hamilton James C
Chief Discovery/Trans Medicine
|
3 682
-2.5%
38,52
141 831
USD
|
3 682
-2.5%
|
38,52
|
141 831
USD
|
|
2023-01-05 |
2023-01-03 |
VP
Vente planifiée
|
Hamilton James C
Chief Discovery/Trans Medicine
|
1 642
-1.1%
37,49
61 559
USD
|
1 642
-1.1%
|
37,49
|
61 559
USD
|
|
2023-01-05 |
2023-01-03 |
VP
Vente planifiée
|
Hamilton James C
Chief Discovery/Trans Medicine
|
136
-0.1%
40,54
5 513
USD
|
136
-0.1%
|
40,54
|
5 513
USD
|
|